Punch & Associates Investment Management Inc. Invests $7.92 Million in MiMedx Group, Inc $MDXG

Punch & Associates Investment Management Inc. purchased a new position in MiMedx Group, Inc (NASDAQ:MDXG) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,058,089 shares of the company’s stock, valued at approximately $7,924,000. Punch & Associates Investment Management Inc. owned about 1.41% of MiMedx Group at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in MDXG. Royal Bank of Canada increased its position in shares of MiMedx Group by 1.4% in the 1st quarter. Royal Bank of Canada now owns 982,532 shares of the company’s stock worth $7,466,000 after purchasing an additional 13,629 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of MiMedx Group by 42.6% during the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in MiMedx Group in the first quarter worth about $232,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after buying an additional 4,049 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in MiMedx Group by 93.9% in the first quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock valued at $9,355,000 after buying an additional 596,016 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Trading Up 1.8%

Shares of NASDAQ MDXG opened at $4.42 on Thursday. MiMedx Group, Inc has a 12-month low of $3.03 and a 12-month high of $7.97. The company has a market cap of $644.26 million, a price-to-earnings ratio of 110.53 and a beta of 1.45. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The stock’s 50 day simple moving average is $4.15 and its 200 day simple moving average is $4.10.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The firm had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. Equities research analysts expect that MiMedx Group, Inc will post -0.1 EPS for the current year.

Wall Street Analysts Forecast Growth

MDXG has been the topic of a number of research analyst reports. Seaport Research Partners downgraded MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Weiss Ratings reiterated a “sell (d)” rating on shares of MiMedx Group in a report on Thursday, August 13th. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Citizens Jmp lowered their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Finally, Raymond James Financial set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.43.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.